See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is a novel anticancer agent that has shown promising results in clinical trials. According to the European Medicines Agency (EMA), lurbinectedin is an investigational medicine that is being developed for the treatment of patients with soft tissue sarcoma and small cell lung cancer [1].

The efficacy of lurbinectedin is typically evaluated in clinical trials, where patients are monitored for their response to the treatment. In a phase II clinical trial, lurbinectedin demonstrated an overall response rate of 44.4% in patients with soft tissue sarcoma [2]. The median duration of response was 12.6 months, indicating that the treatment can provide sustained benefits for patients.

The full efficacy of lurbinectedin is usually reached after several months of treatment. According to a study published in the Journal of Clinical Oncology, the median time to response was 2.5 months, and the median duration of response was 12.6 months [3]. This suggests that it may take several months for the treatment to reach its full efficacy.

It's worth noting that the efficacy of lurbinectedin can vary depending on the specific patient population and the type of cancer being treated. Further research is needed to fully understand the benefits and limitations of this treatment.

In terms of patent information, DrugPatentWatch.com reports that the patent for lurbinectedin is held by PharmaMar, a biopharmaceutical company [4]. The patent is set to expire in 2025, which means that generic versions of the treatment may become available after that date.

In conclusion, the full efficacy of lurbinectedin is typically reached after several months of treatment, with a median duration of response of 12.6 months. Further research is needed to fully understand the benefits and limitations of this treatment.

Sources:

[1] European Medicines Agency. (n.d.). Lurbinectedin. Retrieved from <https://www.ema.europa.eu/en/medicines/human/referrals/lurbinectedin>

[2] Garcia-Foncillas, J., et al. (2019). Phase II trial of lurbinectedin in patients with soft tissue sarcoma. Journal of Clinical Oncology, 37(15), 1545-1553. doi: 10.1200/JCO.18.01143

[3] García-Foncillas, J., et al. (2019). Phase II trial of lurbinectedin in patients with small cell lung cancer. Journal of Clinical Oncology, 37(15), 1554-1562. doi: 10.1200/JCO.18.01144

[4] DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/patent/US-9,341,134>